LivaNova PLC (LIVN)
| Market Cap | 3.51B |
| Revenue (ttm) | 1.39B |
| Net Income (ttm) | -242.47M |
| Shares Out | 54.69M |
| EPS (ttm) | -4.45 |
| PE Ratio | n/a |
| Forward PE | 15.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,885 |
| Open | 64.42 |
| Previous Close | 65.26 |
| Day's Range | 64.42 - 64.94 |
| 52-Week Range | 32.48 - 71.92 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 70.25 (+9.39%) |
| Earnings Date | Feb 25, 2026 |
About LIVN
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing sy... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for LIVN stock is "Strong Buy." The 12-month stock price target is $70.25, which is an increase of 9.39% from the latest price.
News
Artisan International Small-Mid Fund Q4 2025 Performance Review
The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Our portfolio, which has a structural growth orientation, has no...
LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 gui...
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results o...
LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
LivaNova to Present at J.P. Morgan Healthcare Conference in January
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference i...
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (A...
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Ob...
LivaNova to Present at Piper Sandler Healthcare Conference in December
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general...
LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assi...
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap a...
LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript
LivaNova PLC ( LIVN) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Vladimir Makatsaria - CEO & Director Alex Shvartsburg - Chief Financial Officer Ahmet Tezel - Chief Innova...
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-...
LivaNova to Present at Wolfe Research Healthcare Conference in November
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsbur...
LivaNova: Robust Fundamentals, Long-Term Growth Potential
LivaNova remains a 'BUY' with a raised price target of $61/share, reflecting strong recent results and long-term growth potential. LIVN delivered double-digit revenue growth, improved margins, and rai...
LivaNova to Announce Third-Quarter 2025 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5,...
LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) ...
LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
LivaNova PLC (NASDAQ:LIVN) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Vladimir Makatsaria - CEO & Director Alex Shvartsburg - Chief Fi...
LivaNova Appoints Donald Zurbay as a New Director
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of ...
LivaNova to Host Investor Day on November 12, 2025
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025.
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex...
LivaNova Launches Essenz Perfusion System in China
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it initiated the commercial launch of the Essenz™ Perfusion...
LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Briana Got...
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the second quarter ended June 30, 2025, and raised full-year 2025 guidance.
LivaNova to Announce Second-Quarter 2025 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug...